Eldelumab is a humanized anti-CXCL10 (IP-10) monoclonal antibody that binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab has been use for the treatment of ulcerative colitis.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.